BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:177Lu-NNS309 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of 177Lu-NNS309\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06562192-2304@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20310115
DTEND;VALUE=DATE:20310116
SUMMARY:177Lu-NNS309: Phase 1 readout est. (NCT06562192)
DESCRIPTION:177Lu-NNS309\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic\, Lung\, Breas
 t and Colorectal Cancers\nEstimated primary completion: 15 January 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/177lu-nns309#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06562192
URL:https://assetmemo.bio/drug/177lu-nns309#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
